NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

生物相似藥廠商前50大企業 (2021年) :50家主要生物相似藥企業的簡介,各產品、地區的市場分析與預測,自COVID-19的復甦方案

Top 50 Biosimilar Drug Manufacturers 2021: Profiles of Top 50 Leading Biosimilar Companies and Forecasts by Product, plus Regional Market Analysis and COVID-19 Recovery Scenarios

出版商 Visiongain Ltd 商品編碼 983573
出版日期 內容資訊 英文 372 Pages
商品交期: 最快1-2個工作天內
價格
生物相似藥廠商前50大企業 (2021年) :50家主要生物相似藥企業的簡介,各產品、地區的市場分析與預測,自COVID-19的復甦方案 Top 50 Biosimilar Drug Manufacturers 2021: Profiles of Top 50 Leading Biosimilar Companies and Forecasts by Product, plus Regional Market Analysis and COVID-19 Recovery Scenarios
出版日期: 2020年11月06日內容資訊: 英文 372 Pages
簡介

本報告提供全球生物相似藥產業的前20名產品,主要50家公司的定性分析,機會趨勢,及商務評價預測,至2023年的潛在收益的流程,佔全球生物相似藥市場上60%以上的市場佔有率的主要15家公司,重要的市場佔有率,創新的策略性合作與M&A為焦點的20個前導性企業,及對生物相似藥的研究開發進行巨額投資,著重開發新藥的15個成長企業的簡介。

目錄

第1章 報告概要

第2章 摘要整理

第3章 全球生物相似藥市場規模預測

  • 全球生物相似藥市場:收益預測
  • 全球生物相似藥市場:COVID-19復甦預測(V,U,W,L)
    • "V" 字型的復甦-迅速下跌-突然借款-迅速復甦
    • "U" 字型的復甦-早期階段迅速下跌再趨緩-慢慢在下部復甦-最初復甦慢-之後復甦變快
    • "W" 字型的復甦-迅速下跌-迅速復甦-病毒復發-另一個急劇衰退-復甦
    • "L" 字型的復甦-迅速的下跌-此後的成長緩慢

第4章 全球生物相似藥市場規模預測:各產品

  • 全球生物相似藥市場:COVID-19復甦預測(V,U,W,L):各產品
    • "V" 字型的復甦:全球生物相似藥市場,各產品
    • "U" 字型的復甦:全球生物相似藥市場,各產品
    • "W" 字型的復甦:全球生物相似藥市場,各產品
    • "L" 字型的復甦:全球生物相似藥市場,各產品
  • Adalimumab
    • 市場預測
  • Etanercept
  • Trastuzumab
  • Infliximab
  • Insulin Glargine
  • Rituximab
  • Pegfilgrastim
  • 紅血球生成素Alpha
  • 特立帕肽
  • Bevacizumab
  • Insulin Lispro
  • Darbepoetin Alfa
  • Filgrastim
  • Enoxaparin
  • Eculizumab
  • Natalizumab
  • Cetuximab
  • 促濾泡素Alpha
  • 生長激素
  • Dornase Alfa
  • 其他生物相似藥

第5章 地區的生物相似藥市場預測

  • 生物相似藥的主要地區市場為何?
  • 全球生物相似藥市場:COVID-19復甦預測(V,U,W,L),各地區
    • "V" 字型的復甦:全球生物相似藥市場,各地區
    • "U" 字型的復甦:全球生物相似藥市場,各地區
    • "W" 字型的復甦:全球生物相似藥市場,各地區
    • "L" 字型的復甦:全球生物相似藥市場,各地區
  • 北美
    • 市場預測
    • 市場:COVID-19復甦預測(V,U,W,L)
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲

第6章 生物相似藥市場預測:主要企業

  • COVID-19的影響:生物相似藥產業
  • 企業佔有率分析
  • Amgen Inc
  • Novartis AG
  • Merck & Co., Inc
  • Pfizer Inc
  • Eli Lilly and Company
  • Biogen Inc.
  • Teva Pharmaceutical Industries Ltd
  • Celltrion Healthcare Co.,Ltd
  • Sanofi
  • Samsung Bioepis
  • Mylan NV
  • Fresenius Kabi AG
  • Intas Pharmaceuticals Ltd.
  • AbbVie Inc
  • STADA Arzneimittel AG

第7章 生物相似藥市場預測:中階企業

  • Coherus
  • Dr. Reddy's Laboratories Ltd.
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Co Ltd
  • Biocon Ltd
  • Nichi-iko
  • Fujifilm Kyowa Kirin Biologics
  • Zydus Cadila
  • Apotex Inc
  • Lupin
  • PolPharma
  • Zhejiang Hisun Pharma
  • Cipla Ltd
  • Generium
  • Torrent Pharma
  • Shenzhen Techdow Pharmaceutical
  • Mochida
  • Gedeon RichterPlc
  • Aurobindo Pharma
  • USV BIOLOGICS

第8章 生物相似藥市場預測:新加入企業

  • Egis Pharmaceuticals Plc
    • 企業簡介
    • 企業概要
    • 生物相似藥概要
    • 財務
    • 產品系列
    • 最新的開發
  • Hetero
  • Ligand Pharmaceuticals
  • Xbrane
  • Alvotech
  • Mabion SA
  • Reliance Life Sciences
  • Harvest Moon Pharmaceuticals
  • Aryogen
  • Jiangsu Simcere Pharmaceutical Co. Ltd
  • Mundipharma International
  • Kashiv Pharma
  • Gene Techno Science
  • Avesthagen Pharma
  • Formycon AG

第9章 結論、建議

  • 生物相似藥:全球市場
  • 生物相似藥市場上主要企業

第10章 詞彙表

第11章 附錄A

  • 關於Visiongain
  • Visiongain報告評估泡沫
  • 圖表清單
目錄
Product Code: PHA0975

Title:
Top 50 Biosimilar Drug Manufacturers 2021
Profiles of Top 50 Leading Biosimilar Companies and Forecasts by Product (Adalimumab, Etanercept, Trastuzumab, Infliximab, Insulin Glargine, Rituximab, Pegfilgrastim, Epoetin Alfa, Teriparatide, Bevacizumab, Insulin Lispro, Darbepoetin Alfa, Filgrastim, Enoxaparin, Eculizumab, Natalizumab, Cetuximab, Follitropin Alfa, Somatropin, Dornase Alfa). PLUS Regional Market Analysis AND COVID-19 Recovery Scenarios.

Top 50 Biosimilar Companies Report- Read on to determine how you can exploit the impending business opportunities emerging in this sector along with profile of top 50 companies operating in the market. The company profiles are divided into three segments including:

  • Major Players: Profiles of major 15 companies that account for over 60% market share in the global biosimilars market
  • Mid-Range Players: Profiles of 20 pioneering companies that account for significant market share and focuses on the innovative strategic collaborations and M&A
  • Ones to Watch - New Players: Profiles of 15 growing companies that are investing a huge amount of money in biosimilars R&D and focuses on new drug development

The global biosimilars market is projected to reach at a market value of USxx billion by 2023 with a lucrative CAGR during the forecast period. Visiongain's report shows you the potential revenues streams to 2023, assessing the top 20 products, the major 50 key players, qualitative analysis, opportunities trends, and business prospects in the biosimilars industry.

How this report will benefit you

Visiongain's new study is envisioned for anyone requiring commercial in-depth analyses for the global biosimilars market along with detailed company profiles of top 50 companies operating in the market. Our new study assists you to evaluate the overall global and regional market for biosimilars. Get the financial analysis of the overall market and major 50 player's revenue predictions till 2023. High opportunity remains in this fast-growing Biosimilars Market. See how to exploit the existing opportunities in the market to gain maximum advantage in the near future.

Forecasts to 2023 and other analyses reveal the commercial prospects

  • In addition to profiles of top 50 biosimilar companies, our new study provides you with revenue forecasting to 2023
  • Includes growth rates for each segment and regional markets along with COVID-19 impact analysis
  • The profiles of the top 50 companies - descriptive and comprehensive data including company snapshot, overview, commercial developments, company shares & ranking, and detailed financial analysis with revenue and segment revenue forecast till 2023.
  • COVID-19 set to have a positive impact on the biosimilars industry and the report includes detailed analysis and invaluable insight into how COVID-19 will affect the industry.

Discover sales forecasts for the global and regional market forecasts from 2020-2023

Along with revenue prediction for the overall global market, there is segmentations by product for 20 major biosimilar drugs and 5 regional markets including North America, Europe, Asia Pacific, Latin America, and MEA.

Global market revenue and growth forecasts from 2020 to 2023 by product

The global biosimilars market revenue will surpass $16.57 billion in 2020 with a lucrative CAGR during the forecast period 2021-2023 to reach significant revenue growth to 2023.

The major product considered in the report are:

  • Adalimumab
  • Etanercept
  • Trastuzumab
  • Infliximab
  • Insulin Glargine
  • Rituximab
  • Pegfilgrastim
  • Epoetin Alfa
  • Teriparatide
  • Bevacizumab
  • Insulin Lispro
  • Darbepoetin Alfa
  • Filgrastim
  • Enoxaparin
  • Eculizumab
  • Natalizumab
  • Cetuximab
  • Follitropin Alfa
  • Somatropin
  • Dornase Alfa
  • Other Biosimilars

Regional market revenue and growth forecasts from 2020 to 2023:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Leading companies and those seeking to enter the market

The report includes profiles of 50 major companies involved in the Biosimilar Market. The companies profiled in this report include:

Amgen Inc.; Novartis AG; Merck & Co., Inc.; Pfizer Inc.; Eli Lilly and Company; Biogen Inc.; Teva Pharmaceutical Industries Ld.; Celltrion Healthcare Co., Ltd.; Sanofi; Samsung Bioepis; Mylan N.V.; Fresenius Kabi AG; Intas Pharmaceuticals Ltd.; AbbVie Inc.; STADA Arzneimittel AG ; Coherus; Dr Reddy's Laboratories Ltd.; Boehringer Ingelheim International GmbH; Daiichi Sankyo Co Ltd.; Biocon Ltd.; Nichi-Iko; Fujifilm Kyowa Kirin Biologics; Zydus Cadila; Apotex Inc.; Lupin Ltd.; PolPharma; Zhejiang Hisun Pharma; Cipla Ltd.; Generium; Torrent Pharma; Shenzhen Techdow Pharmaceutical; Mochida; Gedeon Richter Plc.; Aurobindo Pharma; USV Biologics; Egis Pharmaceuticals Plc.; Hetero; Ligand Pharmaceuticals; Xbrane Biopharma AB; Alvotech; Mabion S.A.; Reliance Life Sciences; Harvest Moon Pharmaceuticals; AryoGen; Jiangsu Simcere Pharmaceutical; Mundipharma International Ltd.; Kashiv Biosciences; Gene Techno Science; Avesthagen Pharma AG; Formycon AG.

Find qualitative and quantitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

In summary, our 372-page report delivers you with the following knowledge:

  • Revenue forecasts from 2020 to 2023 for the global biosimilars market and subsegments (by products and region)- discover the industry's prospects, finding the most lucrative areas for investments and revenue generation
  • Detailed profiles of Top 50 Biosimilar Companies, with financial forecasts for net revenues, operating income, R&D investment, and biosimilar segment revenue
  • Revenue forecasts from 2020 to 2023 for 5 regional markets - See forecasts for the biosimilars market in North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else

With this new and exclusive report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your investment, research, analyses, and decisions. Visiongain's study is for everybody needing commercial analyses for the Global Biosimilars market and Detailed Analysis of 50 Leading Companies. You will get the most recent data, opportunities, trends, and predictions.

The Top 50 Biosimilar Companies Report Forecast 2020-2023 will be of value to anyone who wants to better understand the market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional market or to understand strategic analysis of leading 50 companies of the biosimilars industry.

Buy our report today Top 50 Biosimilar Drug Manufacturers 2021: Profiles of Top 50 Leading Biosimilar Companies and Forecasts by Product (Adalimumab, Etanercept, Trastuzumab, Infliximab, Insulin Glargine, Rituximab, Pegfilgrastim, Epoetin Alfa, Teriparatide, Bevacizumab, Insulin Lispro, Darbepoetin Alfa, Filgrastim, Enoxaparin, Eculizumab, Natalizumab, Cetuximab, Follitropin Alfa, Somatropin, Dornase Alfa). PLUS Regional Market Analysis AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed - order our report now.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Introduction to Biosimilars Market
  • 1.2. Global Biosimilars Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. What This Report Delivers
  • 1.5. Key Questions Answered By This Analytical Report Include:
  • 1.6. Who is This Report For?
  • 1.7. Methodology
    • 1.1.1 COVID-19 Impact: Recovery Scenarios
    • 1.1.2 Market Evaluation & Forecasting Methodology
  • 1.8. Frequently Asked Questions (FAQs)
  • 1.9. About Visiongain

2 Executive Summary

3 Global Biosimilars Market Size Forecast 2021-2023

  • 3.1 Global Biosimilars Market: Revenue Forecast 2021-2023
  • 3.2 Global Biosimilars Market: COVID-19 Recovery Forecasts (V,U, W, L) 2021-2023
    • 3.2.1 "V" shaped Recovery - Rapid Decline - Sharp Borrow -Rapid Recovery
      • 3.2.1.1 Growing demand for cost-effective biosimilar drugs and patent expiry of biologics during the forecast period
    • 3.2.2 "U" Shaped Recovery -Rapid Decline Early Then Slow - Gradual at the Bottom - Slow Recovery at First - Faster Recovery Later On
      • 3.2.2.1 Players in the market will require to radically rethink their strategies
    • 3.2.3 "W" Shaped Recovery -Rapid Decline - Rapid Recovery- Return of Virus - Another Sharp Decline -Recovery
      • 3.2.3.1 There will be fluctuating growth seen in the revenue and thus market will grow at an irregular rate due to the uneven upraise of COVID-19
    • 3.2.4 "L" Shaped Recovery - Rapid Decline - Then Slow Growth
      • 3.2.4.1 The market will show moderately pessimistic growth

4 Global Biosimilars Market Size Forecast 2021-2023 by Product

  • 4.1 Global Biosimilars Market by Product: COVID-19 Recovery Forecasts (V,U, W, L) 2021-2023
    • 4.1.1 "V" shaped Recovery: Global Biosimilars Market by Product, Revenue Forecast 2021-2023
    • 4.1.2 "U" shaped Recovery: Global Biosimilars Market by Product, Revenue Forecast 2021-2023
    • 4.1.3 "W" shaped Recovery: Global Biosimilars Market by Product, Revenue Forecast 2021-2023
    • 4.1.4 "L" shaped Recovery: Global Biosimilars Market by Product, Revenue Forecast 2021-2023
  • 4.2 Adalimumab
    • 4.2.1 Adalimumab Market Forecast 2021-2023
      • 4.2.1.1 Largest revenue-grossing segment in the global market
  • 4.3 Etanercept
    • 4.3.1 Etanercept Market Forecast 2021-2023
      • 4.3.1.1 One of the best-selling biological products and a lucrative aim for developers of biosimilars
  • 4.4 Trastuzumab
    • 4.4.1 Trastuzumab Market Forecast 2021-2023
      • 4.4.1.1 Widely used for the treatment of pateints with breast cancer
  • 4.5 Infliximab
    • 4.5.1 Infliximab Market Forecast 2021-2023
      • 4.5.1.1 Infliximab segment is is projected to growt at a lucrative CAGR during the forecast period
  • 4.6 Insulin Glargine
    • 4.6.1 Insulin Glargine Market Forecast 2021-2023
      • 4.6.1.1 In both Europe and the US, the patents on Lantus expired in 2014
  • 4.7 Rituximab
    • 4.7.1 Rituximab Market Forecast 2021-2023
      • 4.7.1.1 It is one of the fastest growing segment in the global market
  • 4.8 Pegfilgrastim
    • 4.8.1 Pegfilgrastim Market Forecast 2021-2023
      • 4.8.1.1 Patents for Neulasta expired in October 2015 in the US and expired in August 2017 in Europe
  • 4.9 Epoetin Alfa
    • 4.9.1 Epoetin Alfa Market Forecast 2021-2023
      • 4.9.1.1 Hospira (Pfizer) acquired approval in the US in May 2018 for its epoetin alfa biosimilar, Retacrit (epoetin alfa-epbx)
  • 4.10 Teriparatide
    • 4.10.1 Teriparatide Market Forecast 2021-2023
      • 4.10.1.1 This segment is growing at a lucrative CAGR during the forecast period
  • 4.11 Bevacizumab
    • 4.11.1 Bevacizumab Market Forecast 2021-2023
      • 4.11.1.1 Mainly used to treat different cancers including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers
  • 4.12 Insulin Lispro
    • 4.12.1 Insulin Lispro Market Forecast 2021-2023
      • 4.12.1.1 Insulin lispro is a fast acting analogue of insulin used for the treatment of individuals with type 1 or type 2 diabetes
  • 4.13 Darbepoetin Alfa
    • 4.13.1 Darbepoetin Alfa Market Forecast 2021-2023
      • 4.13.1.1 Aranesp's patents expired in July 2016 in Europe and will expire in the U.S. by May 2024
  • 4.14 Filgrastim
    • 4.14.1 Filgrastim Market Forecast 2021-2023
      • 4.14.1.1 Filgrastim is a colony-stimulating factor (G-CSF) in granulocytes
  • 4.15 Enoxaparin
    • 4.15.1 Enoxaparin Market Forecast 2021-2023
      • 4.15.1.1 Enoxaparin is used for the prevention and treatment of pulmonary embolism or deep vein thrombosis
  • 4.16 Eculizumab
    • 4.16.1 Eculizumab Market Forecast 2021-2023
      • 4.16.1.1 The patents on Soliris will expire in March 2021 in the US and in May 2020 in Europe
  • 4.17 Natalizumab
    • 4.17.1 Natalizumab Market Forecast 2021-2023
      • 4.17.1.1 In September 2019, Sandoz announced that it will commercialize the Polpharma's natalizumab biosimilar while Polpharma will be responsible for development and manufacturing
  • 4.18 Cetuximab
    • 4.18.1 Cetuximab Market Forecast 2021-2023
      • 4.18.1.1 The major vendors including Amgen, BioXPress, Celltrion, and MabTech-Sorrento have cetuximab biosimilar under development
  • 4.19 Follitropin Alfa
    • 4.19.1 Follitropin Alfa Market Forecast 2021-2023
      • 4.19.1.1 There are several popular biosimilars of Follitropin alfa available in the market
  • 4.20 Somatropin
    • 4.20.1 Somatropin Market Forecast 2021-2023
      • 4.20.1.1 It is a peptide hormone in humans and other animals that stimulates growth, cell reproduction, and cell regeneration
  • 4.21 Dornase Alfa
    • 4.21.1 Dornase Alfa Market Forecast 2021-2023
      • 4.21.1.1 In September 2019, the Russian biotech firm Generium and the Swiss cell-line manufacturer Selexis obtained approval for their biological dornase alfa biosimilar Tigerase
  • 4.22 Other Biosimilars
    • 4.22.1 Other Biosimilars Market Forecast 2021-2023
      • 4.22.1.1 Growing demand for advanced and affordable drugs expected to drive the segment growth

5 Regional Biosimilars Market Forecasts 2021-2023

  • 5.1 What Were the Leading Regional Markets for Biosimilar in 2020?
  • 5.2 Global Biosimilars Market by Region: COVID-19 Recovery Forecasts (V,U, W, L) 2021-2023
    • 5.2.1 "V" shaped Recovery: Global Biosimilars Market by Region, Revenue Forecast 2021-2023
    • 5.2.2 "U" shaped Recovery: Global Biosimilars Market by Region, Revenue Forecast 2021-2023
    • 5.2.3 "W" shaped Recovery: Global Biosimilars Market by Region, Revenue Forecast 2021-2023
    • 5.2.4 "L" shaped Recovery: Global Biosimilars Market by Region, Revenue Forecast 2021-2023
  • 5.3 North America
    • 5.3.1 North America Biosimilars Market Forecast 2021-2023
      • 5.3.1.1 Increasing Number of Drug Approvals
      • 5.3.1.2 Presence of Advanced Healthcare Infrastructure and Government Funding
    • 5.3.2 North America Biosimilars Market: COVID-19 Recovery Forecasts (V,U, W, L) 2021-2023
  • 5.4 Europe
    • 5.4.1 Europe Biosimilars Market Forecast 2021-2023
      • 5.4.1.1 The Largest Revenue Grossing Region
      • 5.4.1.2 A Hub for Advanced Drugs Development and Production
    • 5.4.2 Europe Biosimilars Market: COVID-19 Recovery Forecasts (V,U, W, L) 2021-2023
  • 5.5 Asia Pacific
    • 5.5.1 Asia Pacific Biosimilars Market Forecast 2021-2023
      • 5.5.1.1 Increasing Prevalence of Cancer & Autoimmune Diseases
      • 5.5.1.2 An Attractive Market for the Industry Looking to Expand Within the Region
    • 5.5.2 Asia Pacific Biosimilars Market: COVID-19 Recovery Forecasts (V, U, W, L) 2021-2023
  • 5.6 Latin America
    • 5.6.1 Latin America Biosimilars Market Forecast 2021-2023
      • 5.6.1.1 Government Support for Development of the Healthcare Sector
      • 5.6.1.2 Availability of Skilled and Inexpensive Workforce
    • 5.6.2 Latin America Biosimilars Market: COVID-19 Recovery Forecasts (V, U, W, L) 2021-2023
  • 5.7 MEA
    • 5.7.1 MEA Biosimilars Market Forecast 2021-2023
      • 5.7.1.1 Developing Healthcare Infrastructure
      • 5.7.1.2 Presence of huge growth opportunities
    • 5.7.2 MEA Biosimilars Market: COVID-19 Recovery Forecasts (V,U, W, L) 2021-2023

6 Biosimilars Market Forecasts 2021-2023: Major Players

  • 6.1 COVID-19 Impact: Biosimilars Industry
  • 6.2 Company Share Analysis: Biosimilars Market 2020
  • 6.3 Amgen Inc.
    • 6.3.1 Amgen Inc.: Company Snapshot
    • 6.3.2 Amgen: Company Overview
    • 6.3.3 Amgen: Biosimilars Overview
    • 6.3.4 Amgen: Geographical Locations
    • 6.3.5 Amgen: Strategic Planning
    • 6.3.6 Amgen: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 6.3.7 Amgen Inc.: Product Portfolio
    • 6.3.8 Amgen Inc.: Biosimilar Product Pipeline
    • 6.3.9 Amgen Inc.: Company Facilities
    • 6.3.10 Amgen: Latest Developments
  • 6.4 Novartis AG
    • 6.4.1 Novartis AG: Company Snapshot
    • 6.4.2 Novartis AG: Company Overview
    • 6.4.3 Novartis AG: Biosimilars Overview
    • 6.4.4 Novartis AG: Financials, 2018-2023
      • 6.4.4.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 6.4.5 Novartis AG: Product Portfolio
    • 6.4.6 Novartis AG: Latest Developments
  • 6.5 Merck & Co., Inc.
    • 6.5.1 Merck & Co., Inc.: Company Snapshot
    • 6.5.2 Merck & Co., Inc.: Company Overview
    • 6.5.3 Merck & Co., Inc.: Biosimilars Overview
    • 6.5.4 Merck & Co., Inc.: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 6.5.5 Merck & Co., Inc.: Product Portfolio
    • 6.5.6 Merck & Co., Inc.: Latest Developments
  • 6.6 Pfizer Inc.
    • 6.6.1 Pfizer Inc.: Company Snapshot
    • 6.6.2 Pfizer Inc.: Company Overview
    • 6.6.3 Pfizer Inc.: Biosimilars Overview
    • 6.6.4 Pfizer Inc.: Manufacturing Overview
    • 6.6.5 Pfizer Inc.: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 6.6.6 Pfizer Inc.: Product Portfolio
    • 6.6.7 Pfizer Inc.: Latest Developments
  • 6.7 Eli Lilly and Company
    • 6.7.1 Eli Lilly and Company: Company Snapshot
    • 6.7.2 Eli Lilly and Company: Company Overview
    • 6.7.3 Eli Lilly and Company: Biosimilars Overview
    • 6.7.4 Eli Lilly and Company: Regional Presence
    • 6.7.5 Eli Lilly and Company: Company Facilities
    • 6.7.6 Eli Lilly and Company: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 6.7.7 Eli Lilly and Company: Product Portfolio
    • 6.7.8 Eli Lilly and Company: Latest Developments
  • 6.8 Biogen Inc.
    • 6.8.1 Biogen Inc.: Company Snapshot
    • 6.8.2 Biogen Inc.: Company Overview
    • 6.8.3 Biogen Inc.: Biosimilars Overview
    • 6.8.4 Biogen Inc.: Manufacturing Operations
    • 6.8.5 Biogen Inc.: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 6.8.6 Biogen Inc.: Product Portfolio
    • 6.8.7 Biogen Inc.: Latest Developments
  • 6.9 Teva Pharmaceutical Industries Ltd.
    • 6.9.1 Teva Pharmaceutical Industries Ltd.: Company Snapshot
    • 6.9.2 Teva Pharmaceutical Industries Ltd.: Company Overview
    • 6.9.3 Teva Pharmaceutical Industries Ltd.: Biosimilars Overview
    • 6.9.4 Teva Pharmaceutical Industries Ltd.: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 6.9.5 Teva Pharmaceutical Industries: Pharmaceutical Production
    • 6.9.6 Teva Pharmaceutical Industries Ltd.: Product Portfolio
    • 6.9.7 Teva Pharmaceutical Industries Ltd.: Latest Developments
  • 6.10 Celltrion Healthcare Co.,Ltd.
    • 6.10.1 Celltrion Healthcare Co.,Ltd.: Company Snapshot
    • 6.10.2 Celltrion Healthcare Co.,Ltd.: Company Overview
    • 6.10.3 Celltrion Healthcare Co., Ltd.: Manufacturing Facilities
    • 6.10.4 Celltrion Healthcare Co.,Ltd.: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 6.10.5 Celltrion Healthcare Co.,Ltd.: Product Portfolio
    • 6.10.6 Celltrion Healthcare Co., Ltd.: Product in Details
    • 6.10.7 Celltrion Healthcare Co.,Ltd.: Latest Developments
  • 6.11 Sanofi
    • 6.11.1 Sanofi: Company Snapshot
    • 6.11.2 Sanofi: Company Overview
    • 6.11.3 Sanofi: Biosimilar Overview
    • 6.11.4 Sanofi: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 6.11.5 Sanofi: Product Portfolio
    • 6.11.6 Sanofi: Latest Developments
  • 6.12 Samsung Bioepis
    • 6.12.1 Samsung Bioepis: Company Snapshot
    • 6.12.2 Samsung Bioepis: Company Overview
    • 6.12.3 Samsung Bioepis: Biosimilars Overview
    • 6.12.4 Samsung Bioepis: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 6.12.5 Samsung Bioepis: Product Portfolio
    • 6.12.6 Samsung Bioepis: Latest Developments
  • 6.13 Mylan N.V.
    • 6.13.1 Mylan N.V.: Company Snapshot
    • 6.13.2 Mylan N.V.: Company Overview
    • 6.13.3 Mylan N.V.: Biosimilars Overview
    • 6.13.4 Mylan N.V.: Collaboration and Licensing Agreements
    • 6.13.5 Mylan N.V.: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 6.13.6 Mylan N.V.: Product Portfolio
    • 6.13.7 Mylan N.V.: Latest Developments
  • 6.14 Fresenius Kabi AG
    • 6.14.1 Fresenius Kabi AG: Company Snapshot
    • 6.14.2 Fresenius Kabi AG: Company Overview
    • 6.14.3 Fresenius Kabi AG: Biosimilars Overview
    • 6.14.4 Fresenius Kabi AG: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 6.14.5 Fresenius Kabi AG: Product Portfolio
    • 6.14.6 Fresenius Kabi AG: Headquarters
    • 6.14.7 Fresenius Kabi AG: Manufacturing Facilities
    • 6.14.8 Fresenius Kabi AG: Latest Developments
  • 6.15 Intas Pharmaceuticals Ltd.
    • 6.15.1 Intas Pharmaceuticals Ltd.: Company Snapshot
    • 6.15.2 Intas Pharmaceuticals Ltd.: Company Overview
    • 6.15.3 Intas Pharmaceuticals Ltd.: Biosimilar Overview
    • 6.15.4 Intas Pharmaceuticals Ltd.: R&D and Manufacturing Facilities
    • 6.15.5 Intas Pharmaceuticals Ltd.: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 6.15.6 Intas Pharmaceuticals Ltd.: Product Portfolio
    • 6.15.7 Intas Pharmaceuticals Ltd.: Latest Developments
  • 6.16 AbbVie Inc.
    • 6.16.1 AbbVie Inc.: Company Snapshot
    • 6.16.2 AbbVie Inc.: Company Overview
    • 6.16.3 AbbVie Inc. & Allergan plc acquisition & Biosimilar
    • 6.16.4 AbbVie Inc.: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 6.16.5 AbbVie Inc.: Product Portfolio
    • 6.16.6 AbbVie Inc.: Latest Developments
  • 6.17 STADA Arzneimittel AG
    • 6.17.1 STADA Arzneimittel AG: Company Snapshot
    • 6.17.2 STADA Arzneimittel AG: Company Overview
    • 6.17.3 STADA Arzneimittel AG: Biosimilars Overview
    • 6.17.4 STADA Arzneimittel AG: Recent Biosimilars-Related Partnerships
    • 6.17.5 STADA Arzneimittel AG: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 6.17.6 STADA Arzneimittel AG: Product Portfolio
    • 6.17.7 STADA Arzneimittel AG: Latest Developments

7 Biosimilars Market Forecasts 2021-2023: Mid-Range Players

  • 7.1 Coherus
    • 7.1.1 Coherus: Company Snapshot
    • 7.1.2 Coherus: Company Overview
    • 7.1.3 Coherus: Biosimilars Overview
    • 7.1.4 Coherus: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 7.1.5 Coherus: Product Portfolio
    • 7.1.6 Coherus: Latest Developments
  • 7.2 Dr. Reddy's Laboratories Ltd.
    • 7.2.1 Dr. Reddy's Laboratories Ltd.: Company Snapshot
    • 7.2.2 Dr. Reddy's Laboratories Ltd.: Company Overview
    • 7.2.3 Dr. Reddy's Laboratories Ltd.: Biosimilar Overview
    • 7.2.4 Dr. Reddy's Laboratories Ltd.: Future Strategies
    • 7.2.5 Dr. Reddy's Laboratories Ltd.: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 7.2.6 Dr. Reddy's Laboratories Ltd.: Product Portfolio
    • 7.2.7 Dr. Reddy's Laboratories Ltd.: Latest Developments
  • 7.3 Boehringer Ingelheim International GmbH
    • 7.3.1 Boehringer Ingelheim International GmbH: Company Snapshot
    • 7.3.2 Boehringer Ingelheim International GmbH: Company Overview
    • 7.3.3 Boehringer Ingelheim International GmbH: Biosimilars Overview
    • 7.3.4 Boehringer Ingelheim International GmbH: Manufacturing Capacity
    • 7.3.5 Boehringer Ingelheim International GmbH: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 7.3.6 Boehringer Ingelheim International GmbH: Product Portfolio
    • 7.3.7 Boehringer Ingelheim International GmbH: Latest Developments
  • 7.4 Daiichi Sankyo Co Ltd.
    • 7.4.1 Daiichi Sankyo Co Ltd.: Company Snapshot
    • 7.4.2 Daiichi Sankyo Co Ltd.: Company Overview
    • 7.4.3 Daiichi Sankyo Co Ltd.: Biosimilar Overview
    • 7.4.4 Daiichi Sankyo Co Ltd.: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 7.4.5 Daiichi Sankyo Co Ltd.: Product Portfolio
    • 7.4.6 Daiichi Sankyo Co Ltd.: Company Facilities
    • 7.4.7 Daiichi Sankyo Co Ltd.: Latest Developments
  • 7.5 Biocon Ltd.
    • 7.5.1 Biocon Ltd.: Company Snapshot
    • 7.5.2 Biocon Ltd.: Company Overview
    • 7.5.3 Biocon Biologics India Limited
    • 7.5.4 Biocon Ltd.: Biosimilars Overview
    • 7.5.5 Biocon Ltd.: Biosimilars Business Strategic Focus
    • 7.5.6 Biocon Ltd.: Manufacturing Facilities
    • 7.5.7 Biocon Ltd.: Biosimilars Manufacturing Capacity Expansion
    • 7.5.8 Biocon Ltd.: Expanding Commercial Footprint
    • 7.5.9 Biocon Ltd.: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 7.5.10 Biocon Ltd.: Product Portfolio
    • 7.5.11 Biocon Ltd.: Biocon Biologics & Mylan Partnered Portfolio, 2020
    • 7.5.12 Biocon Ltd.: Latest Developments
  • 7.6 Nichi-iko
    • 7.6.1 Nichi-iko: Company Snapshot
    • 7.6.2 Nichi-iko: Company Overview
    • 7.6.3 Nichi-Iko Pharmaceutical Co. Ltd.: Biosimilars Overview
    • 7.6.4 Nichi-iko: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
    • 7.6.5 Nichi-iko: Product Portfolio
    • 7.6.6 Nichi-iko: Latest Developments
  • 7.7 Fujifilm Kyowa Kirin Biologics
    • 7.7.1 Fujifilm Kyowa Kirin Biologics: Company Snapshot
    • 7.7.2 Fujifilm Kyowa Kirin Biologics: Company Profile
    • 7.7.3 Fujifilm Kyowa Kirin Biologics: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 7.7.4 Fujifilm Kyowa Kirin Biologics: Product Portfolio
    • 7.7.5 Fujifilm Kyowa Kirin Biologics: Latest Developments
  • 7.8 Zydus Cadila
    • 7.8.1 Zydus Cadila: Company Snapshot
    • 7.8.2 Zydus Cadila: Company Overview
    • 7.8.3 Zydus Cadila: Biosimilars Overview
    • 7.8.4 Zydus Cadila: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Operating Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 7.8.5 Zydus Cadila: Product Portfolio
    • 7.8.6 Zydus Cadila: Latest Developments
  • 7.9 Apotex
    • 7.9.1 Apotex: Company Snapshot
    • 7.9.2 Apotex Inc.: Company Overview
    • 7.9.3 Apotex Inc.: Biosimilar Overview
    • 7.9.4 Apotex: Manufacturing Facility and Regional Presence
    • 7.9.5 Apotex: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 7.9.6 Apotex: Product Portfolio
    • 7.9.7 Apotex: Latest Developments
  • 7.10 Lupin
    • 7.10.1 Lupin: Company Snapshot
    • 7.10.2 Lupin: Company Overview
    • 7.10.3 Lupin Limited: Biosimilars Overview
    • 7.10.4 Lupin: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Operating Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 7.10.5 Lupin: Product Portfolio
    • 7.10.6 Lupin: Latest Developments
  • 7.11 PolPharma
    • 7.11.1 PolPharma: Company Snapshot
    • 7.11.2 PolPharma: Company Overview
    • 7.11.3 Polpharma: Biosimilars Overview
    • 7.11.4 PolPharma: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 7.11.5 PolPharma: Biosimilars Pipeline
    • 7.11.6 PolPharma: Latest Developments
  • 7.12 Zhejiang Hisun Pharma
    • 7.12.1 Zhejiang Hisun Pharma: Company Snapshot
    • 7.12.2 Zhejiang Hisun Pharma: Company Overview
    • 7.12.3 Zhejiang Hisun Pharma: Biosimilars Overview
    • 7.12.4 Zhejiang Hisun Pharma: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 7.12.5 Zhejiang Hisun Pharma: Biologics Manufacturing Service
    • 7.12.6 Zhejiang Hisun Pharma: Latest Developments
  • 7.13 Cipla Ltd.
    • 7.13.1 Cipla Ltd.: Company Snapshot
    • 7.13.2 Cipla Ltd.: Company Overview
    • 7.13.3 Cipla Ltd.: Manufacturing Investment
    • 7.13.4 Cipla Ltd.: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Profit Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 7.13.5 Cipla Ltd.: Product Portfolio
    • 7.13.6 Cipla Ltd.: Latest Developments
  • 7.14 Generium
    • 7.14.1 Generium: Company Snapshot
    • 7.14.2 Generium: Company Overview
    • 7.14.3 Generium: Biosimilars Overview
    • 7.14.4 Generium: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 7.14.5 Generium: Product Portfolio
    • 7.14.6 Generium: Latest Developments
  • 7.15 Torrent Pharma
    • 7.15.1 Torrent Pharma: Company Snapshot
    • 7.15.2 Torrent Pharma: Company Overview
    • 7.15.3 Torrent Pharma: Biosimilars Overview
    • 7.15.4 Torrent Pharma: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 7.15.5 Torrent Pharma: Product Portfolio
    • 7.15.6 Torrent Pharma: Latest Developments
  • 7.16 Shenzhen Techdow Pharmaceutical
    • 7.16.1 Shenzhen Techdow Pharmaceutical: Company Snapshot
    • 7.16.2 Shenzhen Techdow Pharmaceutical: Company Overview
    • 7.16.3 Shenzhen Techdow Pharmaceutical: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 7.16.4 Shenzhen Techdow Pharmaceutical: Product Portfolio
    • 7.16.5 Shenzhen Techdow Pharmaceutical: Latest Developments
  • 7.17 Mochida
    • 7.17.1 Mochida: Company Snapshot
    • 7.17.2 Mochida: Company Overview
    • 7.17.3 Mochida Pharmaceutical Co. Ltd.: Biosimilars Overview
    • 7.17.4 Mochida: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 7.17.5 Mochida: Product Portfolio
    • 7.17.6 Mochida: Latest Developments
  • 7.18 Gedeon Richter Plc.
    • 7.18.1 Gedeon Richter Plc.: Company Snapshot
    • 7.18.2 Gedeon Richter Plc.: Company Overview
    • 7.18.3 Gedeon Richter Plc.: Biosimilar Overview
    • 7.18.4 Gedeon Richter Plc.: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Operating Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 7.18.5 Gedeon Richter Plc.: Product Portfolio
    • 7.18.6 Gedeon Richter Plc.: Latest Developments
  • 7.19 Aurobindo Pharma
    • 7.19.1 Aurobindo Pharma: Company Snapshot
    • 7.19.2 Aurobindo Pharma: Company Overview
    • 7.19.3 Aurobindo Pharma: Biosimilars Overview
    • 7.19.4 Aurobindo Pharma: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Operating Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 7.19.5 Aurobindo Pharma: Product Portfolio
    • 7.19.6 Aurobindo Pharma: Latest Developments
  • 7.20 USV BIOLOGICS
    • 7.20.1 USV BIOLOGICS: Company Snapshot
    • 7.20.2 USV BIOLOGICS: Company Overview
    • 7.20.3 USV BIOLOGICS: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 7.20.4 USV BIOLOGICS: Product Pipeline
    • 7.20.5 USV BIOLOGICS: Latest Developments

8 Biosimilars Market Forecasts 2021-2023: New Players

  • 8.1 Egis Pharmaceuticals Plc.
    • 8.1.1 Egis Pharmaceuticals Plc.: Company Snapshot
    • 8.1.2 Egis Pharmaceuticals Plc.: Company Overview
    • 8.1.3 EGIS PLC: Biosimilars Overview
    • 8.1.4 Egis Pharmaceuticals Plc.: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 8.1.5 Egis Pharmaceuticals Plc.: Product Portfolio
    • 8.1.6 Egis Pharmaceuticals Plc.: Latest Developments
  • 8.2 Hetero
    • 8.2.1 Hetero: Company Snapshot
    • 8.2.2 Hetero: Company Overview
    • 8.2.3 Hetero: Biosimilars Overview
    • 8.2.4 Hetero: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 8.2.5 Hetero: Product Portfolio
    • 8.2.6 Hetero: Latest Developments
  • 8.3 Ligand Pharmaceuticals
    • 8.3.1 Ligand Pharmaceuticals: Company Snapshot
    • 8.3.2 Ligand Pharmaceuticals: Company Overview
    • 8.3.3 Ligand Pharmaceuticals Inc: Biosimilars Overview
    • 8.3.4 Ligand Pharmaceuticals: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 8.3.5 Ligand Pharmaceuticals: Product Portfolio
    • 8.3.6 Ligand Pharmaceuticals: Latest Developments
  • 8.4 Xbrane
    • 8.4.1 Xbrane: Company Snapshot
    • 8.4.2 Xbrane: Company Overview
    • 8.4.3 Xbrane Biopharma AB: Biosimilars Overview
    • 8.4.4 Xbrane: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Operating Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 8.4.5 Xbrane: Product Portfolio
    • 8.4.6 Xbrane: Latest Developments
  • 8.5 Alvotech
    • 8.5.1 Alvotech: Company Snapshot
    • 8.5.2 Alvotech: Company Overview
    • 8.5.3 Alvotech: R&D and Manufacturing of Biosimilars
    • 8.5.4 Alvotech: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 8.5.5 Alvotech: Product Portfolio
    • 8.5.6 Alvotech: Latest Developments
  • 8.6 Mabion S.A.
    • 8.6.1 Mabion S.A.: Company Snapshot
    • 8.6.2 Mabion S.A.: Company Overview
    • 8.6.3 Mabion S.A.: Biosimilar Overview
    • 8.6.4 Mabion S.A.: Ground-breaking Research & Development Capacity
    • 8.6.5 Mabion S.A.: MabionCD20
    • 8.6.6 Mabion S.A.: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
    • 8.6.7 Mabion S.A.: Product Portfolio
    • 8.6.8 Mabion S.A.: Latest Developments
  • 8.7 Reliance Life Sciences
    • 8.7.1 Reliance Life Sciences: Company Snapshot
    • 8.7.2 Reliance Life Sciences: Company Overview
    • 8.7.3 Reliance Life Sciences: Biosimilars Overview
    • 8.7.4 Reliance Life Sciences: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 8.7.5 Reliance Life Sciences: Product Portfolio
    • 8.7.6 Reliance Life Sciences: Latest Developments
  • 8.8 Harvest Moon Pharma
    • 8.8.1 Harvest Moon Pharmaceuticals: Company Snapshot
    • 8.8.2 Harvest Moon Pharmaceuticals: Company Overview
    • 8.8.3 Harvest Moon Pharmaceuticals: Biosimilars Overview
    • 8.8.4 Harvest Moon Pharmaceuticals: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 8.8.5 Harvest Moon Pharmaceuticals: Product Portfolio
  • 8.9 Aryogen
    • 8.9.1 Aryogen: Company Snapshot
    • 8.9.2 Aryogen: Company Overview
    • 8.9.3 Aryogen: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 8.9.4 Aryogen: Product Portfolio
    • 8.9.5 Aryogen: Latest Developments
  • 8.10 Jiangsu Simcere Pharmaceutical Co., Ltd.
    • 8.10.1 Jiangsu Simcere Pharmaceutical: Company Snapshot
    • 8.10.2 Jiangsu Simcere Pharmaceutical: Company Overview
    • 8.10.3 Jiangsu Simcere Pharmaceutical: Biosimilars Overview
    • 8.10.4 Jiangsu Simcere Pharmaceutical: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 8.10.5 Jiangsu Simcere Pharmaceutical: Product Portfolio
    • 8.10.6 Jiangsu Simcere Pharmaceutical: Latest Developments
  • 8.11 Mundipharma
    • 8.11.1 Mundipharma International: Company Snapshot
    • 8.11.2 Mundipharma International: Company Overview
    • 8.11.3 Mundipharma International: Biosimilar Overview
    • 8.11.4 Mundipharma International: Manufacturing Facilities
    • 8.11.5 Mundipharma International: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 8.11.6 Mundipharma International: Product Portfolio
    • 8.11.7 Mundipharma International: Latest Developments
  • 8.12 Kashiv Pharma
    • 8.12.1 Kashiv Pharma: Company Snapshot
    • 8.12.2 Kashiv Pharma: Company Overview
    • 8.12.3 Kashiv Biosciences: Biosimilars Overview
    • 8.12.4 Kashiv Pharma: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 8.12.5 Kashiv Pharma: Product Portfolio
    • 8.12.6 Kashiv Pharma: Latest Developments
  • 8.13 Gene Techno Science
    • 8.13.1 Gene Techno Science: Company Snapshot
    • 8.13.2 Gene Techno Science: Company Overview
    • 8.13.3 Gene Techno Science: Biosimilars Overview
    • 8.13.4 Gene Techno Science: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
    • 8.13.5 Gene Techno Science: Product Portfolio
    • 8.13.6 Gene Techno Science: Pipeline Portfolio
    • 8.13.7 Gene Techno Science: Latest Developments
  • 8.14 Avesthagen Pharma
    • 8.14.1 Avesthagen: Company Snapshot
    • 8.14.2 Avesthagen: Company Overview
    • 8.14.3 Avesthagen: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.2 Biosimilar Segment Revenue Forecast 2018-2023 ($mn)
    • 8.14.4 Avesthagen: Product Portfolio
  • 8.15 Formycon AG
    • 8.15.1 Formycon AG: Company Snapshot
    • 8.15.2 Formycon AG: Company Overview
    • 8.15.3 Formycon AG: Financials, 2018-2023
      • 6.3.6.1 Net Revenue Forecast 2018-2023 ($mn)
      • 6.3.6.3 Net Income Forecast 2018-2023 ($mn)
      • 6.3.6.4 R&D Investment Forecast 2018-2023 ($mn)
    • 8.15.4 Formycon AG: Pipeline Portfolio
    • 8.15.5 Formycon AG: Latest Developments

9 Conclusions and Recommendations

  • 9.1 Biosimilars: World Market, 2020-2023
  • 9.2 Leading Companies in the Biosimilar Market

10 Glossary

  • 10.1 Associated Visiongain Reports

11 Appendix A

  • 11.1 About Visiongain
  • 11.2 Visiongain report evaluation form
  • LIST OF TABLES
  • Table 1 Global Biosimilars Market, 2021-2023 (US$ billion, CAGR %)
  • Table 2 Global Biosimilars Market: Revenue Forecast 2021-2023 (US$ billion, AGR%, CAGR%)
  • Table 3 "V" Shaped Recovery: Global Biosimilars Market, Revenue Forecast 2021-2023 (US$ billion, AGR%, CAGR%)
  • Table 4 "U" Shaped Recovery: Global Biosimilars Market, Revenue Forecast 2021-2023 (US$ billion, AGR%, CAGR%)
  • Table 5 "W" Shaped Recovery: Global Biosimilars Market, Revenue Forecast 2021-2023 (US$ billion, AGR%, CAGR%)
  • Table 6 "L" Shaped Recovery: Global Biosimilars Market, Revenue Forecast 2021-2023 (US$ billion, AGR%, CAGR%)
  • Table 7 Global Biosimilars Market Forecast by Product, 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 8 "V" Shaped Recovery: Global Biosimilars Market by Product, Revenue Forecast 2021-2023 (US$ billion, AGR%, CAGR%)
  • Table 9 "U" Shaped Recovery: Global Biosimilars Market by Product, Revenue Forecast 2021-2023 (US$ billion, AGR%, CAGR%)
  • Table 10 "W" Shaped Recovery: Global Biosimilars Market by Product, Revenue Forecast 2021-2023 (US$ billion, AGR%, CAGR%)
  • Table 11 "L" Shaped Recovery: Global Biosimilars Market by Product, Revenue Forecast 2021-2023 (US$ billion, AGR%, CAGR%)
  • Table 12 Etanercept Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 13 Etanercept Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 14 Trastuzumab Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 15 Infliximab Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 16 Insulin Glargine Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 17 Rituximab Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 18 Pegfilgrastim Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 19 Epoetin Alfa Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 20 Teriparatide Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 21 Bevacizumab Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 22 Insulin Lispro Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 23 Darbepoetin Alfa Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 24 Filgrastim Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 25 Enoxaparin Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 26 Eculizumab Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 27 Natalizumab Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 28 Cetuximab Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 29 Follitropin Alfa Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 30 Somatropin Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 31 Dornase Alfa Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 32 Other Biosimilars Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 33 Global Biosimilar Regional Markets, 2020 & 2023 (US$ billion, % Share)
  • Table 34 Global Biosimilars Market Forecast by Region, 2021-2023 (US$ billion, AGR %)
  • Table 35 "V" Shaped Recovery: Global Biosimilars Market by Region, Revenue Forecast 2021-2023 (US$ billion, AGR%, CAGR%)
  • Table 36 "U" Shaped Recovery: Global Biosimilars Market by Region, Revenue Forecast 2021-2023 (US$ billion, AGR%, CAGR%)
  • Table 37 "W" Shaped Recovery: Global Biosimilars Market by Region, Revenue Forecast 2021-2023 (US$ billion, AGR%, CAGR%)
  • Table 38 "L" Shaped Recovery: Global Biosimilars Market by Region, Revenue Forecast 2021-2023 (US$ billion, AGR%, CAGR%)
  • Table 39 North America Biosimilars Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 40 Europe Biosimilars Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 41 Asia Pacific Biosimilars Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 42 Latin America Biosimilars Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 43 MEA Biosimilars Market Forecast 2021-2023 (US$ billion, AGR %, CAGR %)
  • Table 44 Amgen Inc. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 45 Amgen Inc.: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 46 Amgen: Product Portfolio
  • Table 47 Amgen: Product Pipeline
  • Table 48 Amgen Inc.: Facility Capabilities, 2020
  • Table 49 Amgen: Latest Developments
  • Table 50 Novartis AG Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 51 Novartis AG: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 52 Novartis AG: Product Portfolio
  • Table 53 Novartis AG: Latest Developments
  • Table 54 Merck & Co., Inc. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 55 Merck & Co. Inc.: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 56 Merck & Co., Inc.: Product Portfolio
  • Table 57 Merck & Co., Inc.: Latest Developments
  • Table 58 Pfizer Inc. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 59 Pfizer Inc.: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 60 Pfizer Inc.: Product Portfolio
  • Table 61 Pfizer Inc.: Latest Developments
  • Table 62 Eli Lilly and Company Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 63 Eli Lilly and Company: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 64 Eli Lilly and Company: Product Portfolio
  • Table 65 Eli Lilly and Company: Latest Developments
  • Table 66 Biogen Inc. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 67 Biogen Inc.: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 68 Biogen Inc.: Product Portfolio
  • Table 69 Biogen Inc.: Latest Developments
  • Table 70 Teva Pharmaceutical Industries Ltd. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 71 Teva Pharmaceutical Industries: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 72 Teva Pharmaceutical Industries Ltd.: Product Portfolio
  • Table 73 Teva Pharmaceutical Industries Ltd.: Latest Developments
  • Table 74 Celltrion Healthcare Co.,Ltd. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 75 Celltrion Healthcare Co.,Ltd: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 76 Celltrion Healthcare Co.,Ltd.: Product Portfolio
  • Table 77 Celltrion Healthcare Co.,Ltd.: Latest Developments
  • Table 78 Sanofi Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 79 Sanofi: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 80 Sanofi: Product Portfolio
  • Table 81 Sanofi: Latest Developments
  • Table 82 Samsung Bioepis Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 83 Samsung Bioepis: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 84 Samsung Bioepis: Product Portfolio
  • Table 85 Samsung Bioepis: Latest Developments
  • Table 86 Mylan N.V. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 87 Mylan N.V.: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 88 Mylan N.V.: Product Portfolio
  • Table 89 Mylan N.V.: Latest Developments
  • Table 90 Fresenius Kabi AG Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 91 Fresenius Kabi AG: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 92 Fresenius Kabi AG: Product Portfolio
  • Table 93 Fresenius Kabi AG: Latest Developments
  • Table 94 Intas Pharmaceuticals Ltd. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 95 Intas Pharmaceuticals Ltd: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 96 Intas Pharmaceuticals Ltd.: Product Portfolio
  • Table 97 Intas Pharmaceuticals Ltd.: Latest Developments
  • Table 98 AbbVie Inc. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 99 AbbVie Inc.: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 100 AbbVie Inc.: Product Portfolio
  • Table 101 AbbVie Inc.: Latest Developments
  • Table 102 STADA Arzneimittel AG Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 103 STADA Arzneimittel AG: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 104 STADA Arzneimittel AG: Product Portfolio
  • Table 105 STADA Arzneimittel AG: Latest Developments
  • Table 106 Coherus Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 107 Coherus: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 108 Coherus: Product Portfolio
  • Table 109 Coherus: Latest Developments
  • Table 110 Dr. Reddy's Laboratories Ltd. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 111 Dr. Reddy's Laboratories Ltd.: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 112 Dr. Reddy's Laboratories Ltd.: Product Portfolio
  • Table 113 Dr. Reddy's Laboratories Ltd.: Latest Developments
  • Table 114 Boehringer Ingelheim International GmbH Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 115 Boehringer Ingelheim International GmbH: Manufacturing Facilities
  • Table 116 Boehringer Ingelheim: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 117 Boehringer Ingelheim International GmbH: Product Portfolio
  • Table 118 Boehringer Ingelheim International GmbH: Latest Developments
  • Table 119 Daiichi Sankyo Co Ltd. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 120 Daiichi Sankyo Co Ltd: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 121 Daiichi Sankyo Co Ltd.: Product Portfolio
  • Table 122 Daiichi Sankyo Co Ltd.: Facility Capabilities, 2020
  • Table 123 Daiichi Sankyo Co Ltd.: Latest Developments
  • Table 124 Biocon Ltd. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 125 Biocon Ltd.: Product Portfolio
  • Table 126 Biocon Ltd.: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 127 Biocon Ltd.: Product Portfolio
  • Table 128 Biocon Ltd.: Facility Capabilities, 2020
  • Table 129 Biocon Ltd.: Latest Developments
  • Table 130 Nichi-iko Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Biosimilars Revenue, Website)
  • Table 131 Nichi-iko: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 132 Nichi-iko: Product Portfolio
  • Table 133 Nichi-iko: Latest Developments
  • Table 134 Fujifilm Kyowa Kirin Biologics Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 135 Fujifilm Kyowa Kirin Biologics: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 136 Fujifilm Kyowa Kirin Biologics: Product Portfolio
  • Table 137 Fujifilm Kyowa Kirin Biologics: Latest Developments
  • Table 138 Zydus Cadila Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 139 Zydus Cadila: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 140 Zydus Cadila: Product Portfolio
  • Table 141 Zydus Cadila: Latest Developments
  • Table 142 Apotex Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 143 Apotex: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 144 Apotex: Product Portfolio
  • Table 145 Apotex: Latest Developments
  • Table 146 Lupin Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 147 Lupin: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 148 Lupin: Product Portfolio
  • Table 149 Lupin: Latest Developments
  • Table 150 PolPharma Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 151 PolPharma: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 152 PolPharma: Biosimilars Pipeline
  • Table 153 PolPharma: Latest Developments
  • Table 154 Zhejiang Hisun Pharma Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 155 Zhejiang Hisun Pharma: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 156 Zhejiang Hisun Pharma: Biologics Manufacturing Service
  • Table 157 Zhejiang Hisun Pharma: Latest Developments
  • Table 158 Cipla Ltd. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 159 Cipla Ltd.: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 160 Cipla Ltd.: Product Portfolio
  • Table 161 Cipla Ltd.: Latest Developments
  • Table 162 Generium Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 163 Generium: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 164 Generium: Product Portfolio
  • Table 165 Generium: Latest Developments
  • Table 166 Torrent Pharma Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 167 Torrent Pharma: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 168 Torrent Pharma: Product Portfolio
  • Table 169 Torrent Pharma: Latest Developments
  • Table 170 Shenzhen Techdow Pharmaceutical Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 171 Shenzhen Techdow Pharmaceutical: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 172 Shenzhen Techdow Pharmaceutical: Product Portfolio
  • Table 173 Shenzhen Techdow Pharmaceutical: Latest Developments
  • Table 174 Mochida Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 175 Mochida: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 176 Mochida: Product Portfolio
  • Table 177 Mochida: Latest Developments
  • Table 178 Gedeon Richter Plc. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 179 Gedeon Richter Plc.: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 180 Gedeon Richter Plc.: Product Portfolio
  • Table 181 Gedeon Richter Plc.: Latest Developments
  • Table 182 Aurobindo Pharma Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 183 Aurobindo Pharma: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 184 Aurobindo Pharma: Product Portfolio
  • Table 185 Aurobindo Pharma: Latest Developments
  • Table 186 USV BIOLOGICS Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 187 USV BIOLOGICS: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 188 USV BIOLOGICS: Product Pipeline
  • Table 189 USV BIOLOGICS: Latest Developments
  • Table 190 Egis Pharmaceuticals Plc. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 191 Egis Pharmaceuticals Plc.: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 192 Egis Pharmaceuticals Plc.: Product Portfolio
  • Table 193 Egis Pharmaceuticals Plc.: Latest Developments
  • Table 194 Hetero Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 195 Hetero: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 196 Hetero: Product Portfolio
  • Table 197 Hetero: Latest Developments
  • Table 198 Ligand Pharmaceuticals Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 199 Ligand Pharmaceuticals: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 200 Ligand Pharmaceuticals: Product Portfolio
  • Table 201 Ligand Pharmaceuticals: Latest Developments
  • Table 202 Xbrane Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 203 Xbrane: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 204 Xbrane: Product Portfolio
  • Table 205 Xbrane: Latest Developments
  • Table 206 Alvotech Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 207 Alvotech: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 208 Alvotech: Product Portfolio
  • Table 209 Alvotech: Latest Developments
  • Table 210 Mabion S.A. Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 211 Mabion S.A.: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 212 Mabion S.A.: Product Portfolio
  • Table 213 Mabion S.A.: Latest Developments
  • Table 214 Reliance Life Sciences Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 215 Reliance Life Sciences: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 216 Reliance Life Sciences: Product Portfolio
  • Table 217 Reliance Life Sciences: Latest Developments
  • Table 218 Harvest Moon Pharmaceuticals Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 219 Harvest Moon Pharmaceuticals: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 220 Harvest Moon Pharmaceuticals: Product Portfolio
  • Table 221 Aryogen Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 222 Aryogen: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 223 Aryogen: Product Portfolio
  • Table 224 Aryogen: Latest Developments
  • Table 225 Jiangsu Simcere Pharmaceutical Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 226 Jiangsu Simcere Pharmaceutical: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 227 Jiangsu Simcere Pharmaceutical: Product Portfolio
  • Table 228 Jiangsu Simcere Pharmaceutical: Latest Developments
  • Table 229 Mundipharma International Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 230 Mundipharma International: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 231 Mundipharma International: Product Portfolio
  • Table 232 Mundipharma International: Latest Developments
  • Table 233 Kashiv Pharma Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 234 Kashiv Pharma: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 235 Kashiv Pharma: Product Portfolio
  • Table 236 Kashiv Pharma: Latest Developments
  • Table 237 Gene Techno Science Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 238 Gene Techno Science: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 239 Gene Techno Science: Product Portfolio
  • Table 240 Gene Techno Science: Pipeline Portfolio
  • Table 241 Gene Techno Science: Latest Developments
  • Table 242 Avesthagen Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 243 Avesthagen: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 244 Avesthagen: Product Portfolio
  • Table 245 Formycon AG Profile 2020 (CEO, HQ, Founded, No. of Employees, Business Segment, Key Capacities, Biosimilars Revenue, Website)
  • Table 246 Formycon AG: Financials ($mn), 2018-2023 (US$ million, AGR %, CAGR %)
  • Table 247 Formycon AG: Pipeline Portfolio
  • Table 248 Formycon AG: Latest Developments

List of Figures

  • Figure 1 Global Biosimilars Market Segmentation
  • Figure 2 Global Biosimilars Market, Revenue Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 3 "V" Shaped Recovery: Global Biosimilars Market, Revenue Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 4 "U" Shaped Recovery: Global Biosimilars Market, Revenue Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 5 "W" Shaped Recovery: Global Biosimilars Market, Revenue Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 6 "L" Shaped Recovery: Global Biosimilars Market, Revenue Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 7 Adalimumab Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 8 Etanercept Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 9 Trastuzumab Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 10 Infliximab Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 11 Insulin Glargine Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 12 Rituximab Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 13 Pegfilgrastim Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 14 Epoetin Alfa Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 15 Teriparatide Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 16 Bevacizumab Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 17 Insulin Lispro Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 18 Darbepoetin Alfa Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 19 Filgrastim Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 20 Enoxaparin Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 21 Eculizumab Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 22 Natalizumab Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 23 Cetuximab Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 24 Follitropin Alfa Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 25 Somatropin Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 26 Dornase Alfa Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 27 Other Biosimilars Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 28 North America Biosimilars Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 29 "V" Shaped Recovery: North America Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 30 "U" Shaped Recovery: North America Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 31 "W" Shaped Recovery: North America Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 32 "L" Shaped Recovery: North America Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 33 Europe Biosimilars Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 34 "V" Shaped Recovery: Europe Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 35 "U" Shaped Recovery: Europe Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 36 "W" Shaped Recovery: Europe Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 37 "L" Shaped Recovery: Europe Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 38 Asia Pacific Biosimilars Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 39 "V" Shaped Recovery: Asia Pacific Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 40 "U" Shaped Recovery: Asia Pacific Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 41 "W" Shaped Recovery: Asia Pacific Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 42 "L" Shaped Recovery: Asia Pacific Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 43 Latin America Biosimilars Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 44 "V" Shaped Recovery: Latin America Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 45 "U" Shaped Recovery: Latin America Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 46 "W" Shaped Recovery: Latin America Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 47 "L" Shaped Recovery: Latin America Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 48 MEA Biosimilars Market Forecast 2021-2023 (US$ billion, AGR %)
  • Figure 49 "V" Shaped Recovery: MEA Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 50 "U" Shaped Recovery: MEA Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 51 "W" Shaped Recovery: MEA Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 52 "L" Shaped Recovery: MEA Biosimilars Market Forecast, 2020-2023 (US$ billion, AGR%)
  • Figure 53 Company Share Analysis: Biosimilars Market 2020
  • Figure 54 Amgen: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 55 Amgen Inc.: Segment Revenue Share (%), 2020
  • Figure 56 Amgen Inc.: Segment Revenue Share (%), 2020
  • Figure 57 Novartis AG: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 58 Novartis AG: Segment Revenue Share (%), 2020
  • Figure 59 Novartis AG: Regional Segment Revenue Share (%), 2020
  • Figure 60 Sandoz: Segment Revenue Share (%), 2020
  • Figure 61 Merck & Co. Inc.: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 62 Merck & Co., Inc.: Segment Revenue Share (%), 2020
  • Figure 63 Merck & Co., Inc.: Regional Segment Revenue Share (%), 2020
  • Figure 64 Pfizer Inc.: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 65 Pfizer Inc.: Segment Revenue Share (%), 2020
  • Figure 66 Pfizer Inc.: Segment Revenue Share (%), 2020
  • Figure 67 Eli Lilly and Company: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 68 Eli Lilly and Company: Segment Revenue Share (%), 2020
  • Figure 69 Eli Lilly and Company: Segment Revenue Share (%), 2020
  • Figure 70 Biogen Inc.: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 71 Biogen Inc.: Segment Revenue Share (%), 2020
  • Figure 72 Biogen Inc.: Product Segment Revenue Share (%), 2020
  • Figure 73 Biogen Inc.: Segment Revenue Share (%), 2020
  • Figure 74 Teva Pharmaceutical Industries Ltd.: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 75 Teva Pharmaceutical Industries Ltd.: Segment Revenue Share (%), 2020
  • Figure 76 Teva Pharmaceutical Industries Ltd.: Segment Revenue Share (%), 2020
  • Figure 77 Celltrion Healthcare Co.,Ltd: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 78 Sanofi: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 79 Sanofi: Segment Revenue Share (%), 2020
  • Figure 80 Sanofi: Segment Revenue Share (%), 2020
  • Figure 81 Samsung Bioepis: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 82 Samsung Bioepis: Segment Revenue Share (%), 2020
  • Figure 83 Samsung Bioepis: Regional Revenue Share (%), 2020
  • Figure 84 Mylan N.V.: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 85 Mylan N.V.: Segment Revenue Share (%), 2020
  • Figure 86 Mylan N.V.: Segment Revenue Share (%), 2020
  • Figure 87 Fresenius Kabi AG: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 88 Fresenius Kabi AG: Segment Revenue Share (%), 2020
  • Figure 89 Fresenius Kabi AG: Segment Revenue Share (%), 2020
  • Figure 90 Intas Pharmaceuticals Ltd.: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 91 Intas Pharmaceuticals Ltd.: Segment Revenue Share (%), 2020
  • Figure 92 AbbVie Inc.: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 93 STADA Arzneimittel AG: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 94 STADA Arzneimittel AG: Segment Revenue Share (%), 2020
  • Figure 95 Coherus: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 96 Coherus: Segment Revenue Share (%), 2020
  • Figure 97 Dr. Reddy's Laboratories Ltd.: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 98 Dr. Reddy's Laboratories Ltd.: Segment Revenue Share (%), 2020
  • Figure 99 Boehringer Ingelheim International GmbH: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 100 Boehringer Ingelheim International GmbH: Segment Revenue Share (%), 2020
  • Figure 101 Boehringer Ingelheim International GmbH: Segment Revenue Share (%), 2020
  • Figure 102 Daiichi Sankyo Co Ltd.: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 103 Daiichi Sankyo Co Ltd.: Segment Revenue Share (%), 2020
  • Figure 104 Daiichi Sankyo Co Ltd.: Segment Revenue Share (%), 2020
  • Figure 105 Biocon Ltd.: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 106 Biocon Ltd.: Segment Revenue Share (%), 2020
  • Figure 107 Nichi-iko: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 108 Fujifilm Kyowa Kirin Biologics: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 109 Fujifilm Kyowa Kirin Biologics: Segment Revenue Share (%), 2020
  • Figure 110 Zydus Cadila: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 111 Zydus Cadila: Segment Revenue Share (%), 2020
  • Figure 112 Zydus Cadila: Regional Revenue Share (%), 2020
  • Figure 113 Apotex: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 114 Lupin: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 115 PolPharma: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 116 Zhejiang Hisun Pharma: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 117 Cipla Ltd.: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 118 Cipla Ltd.: Segment Revenue Share (%), 2020
  • Figure 119 Cipla Ltd.: Regional Revenue Share (%), 2020
  • Figure 120 Generium: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 121 Torrent Pharma: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 122 Torrent Pharma: Regional Revenue Share (%), 2020
  • Figure 123 Shenzhen Techdow Pharmaceutical: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 124 Mochida: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 125 Gedeon Richter Plc.: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 126 Gedeon Richter Plc.: Segment Revenue Share (%), 2020
  • Figure 127 Gedeon Richter Plc.: Regional Revenue Share (%), 2020
  • Figure 128 Aurobindo Pharma: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 129 Aurobindo Pharma: Segment Revenue Share (%), 2020
  • Figure 130 USV BIOLOGICS: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 131 Egis Pharmaceuticals Plc.: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 132 Hetero: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 133 Ligand Pharmaceuticals: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 134 Ligand Pharmaceuticals: Segment Revenue (%), 2020
  • Figure 135 Xbrane: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 136 Xbrane: Segment Revenue Share (%), 2020
  • Figure 137 Xbrane: Regional Revenue Share (%), 2020
  • Figure 138 Alvotech: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 139 Mabion S.A.: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 140 Reliance Life Sciences: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 141 Harvest Moon Pharmaceuticals: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 142 Aryogen: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 143 Jiangsu Simcere Pharmaceutical: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 144 Mundipharma International: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 145 Kashiv Pharma: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 146 Gene Techno Science: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 147 Avesthagen: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 148 Formycon AG: Revenue ($mn) & AGR (%), 2018-2023
  • Figure 149 Global Biosimilars Market, Revenue Forecast 2021-2023 (US$ billion, AGR%)
  • Figure 150 Company Share Analysis: Biosimilars Market 2020

Companies Profiled in the Report:

  • AbbiVie
  • Alvotech
  • Amgen
  • Apotex/Apobiologix
  • Aryogen
  • Aurobindo Pharma
  • Avesthagen Ltd.
  • Biocon
  • Biogen
  • Boehringer Ingelheim
  • Celltrion
  • Cipla
  • Coherus BioSciences, Inc.
  • Daiichi Sankyo Company Ltd
  • Dr. Reddy's
  • Egis Pharmaceuticals PLC
  • Eli Lilly
  • Formycon
  • Fresenius Kabi
  • Fujifilm Kyowa Kirin Biologics
  • Gedeon Richter
  • Gene Techno Science
  • Generium
  • Harvest Moon Pharma
  • Hetero
  • Intas Pharmaceuticals Ltd.
  • Jiangsu Simcere Pharmaceutical Co., Ltd.
  • Kashiv Pharma
  • Ligand Pharmaceuticals
  • Lupin
  • Mabion
  • Merck & Co.
  • Mochida
  • Mundipharma Biologics
  • Mylan
  • Nichi-iko
  • Pfizer
  • PolPharma
  • Reliance Life Sciences
  • Samsung Bioepis
  • Sandoz -Novartis
  • Sanofi
  • Shenzhen Techdow Pharmaceutical
  • STADA Arzneimittel AG
  • Teva
  • Torrent Pharma
  • USV BIOLOGICS
  • Xbrane
  • Zhejiang Hisun Pharma
  • Zydus Cadila

List of Companies Mentioned in the Report:

  • Abdi Ibrahim Pharmaceuticals
  • Adello biologics
  • AffaMed Therapeutics
  • Appobiologix
  • Aprogen Biologics Inc.
  • AYUMI Pharmaceutical
  • Baliopharm GmbH
  • Baush + Lomb
  • Bio-Thera
  • Bioeq
  • Cadila Healthcare
  • Celltrion Healthcare Hungary Kft
  • Cinfa Biotech
  • Cipla Gulf FZ LLC
  • CuraTeQ Biologics Private Limited
  • DSM Pentapharm
  • Fuji Pharma
  • GI Innovation
  • Hisun BioRay Bio Pharmaceutical Co. Ltd.
  • Innovent Biologics
  • Intract Pharma Ltd.
  • JAMP Pharma
  • JW Pharmaceutical
  • Kamada Limited
  • Kishi Kasei Co., Ltd.
  • mAbxience
  • Mycenax
  • Nan Fung Group
  • Prestige Biopharma
  • Revance
  • Sagent Pharmaceuticals
  • Selexis
  • Synthorx
  • TR-Pharm
  • Translate Bio
  • Ultragenyx Pharmaceutical Inc.
  • Wockhardt Limited
  • YL Biologics
  • Yoshindo

List of Organizations Mentioned in the Report:

  • ANDA
  • Centers for Disease Control and Prevention (CDC)
  • Centers for Medicare & Medicaid Services (CMS)
  • Changchun High & New Technology Industries Group Inc. (CCHN)
  • CSIR-NCL and the DST
  • EMA
  • European Commission (EC)
  • Global Burden of Disease Study
  • Japanese Ministry of Health, Labour and Welfare
  • Japanese Ministry of Health, Labour and Welfare
  • National Center for Biotechnology Information (NCBI)
  • National Health Service (NHS)
  • National Psoriasis Foundation
  • NHS
  • NMPA's
  • Organization for Economic Cooperation and Development (OECD)
  • PAG
  • Pharmaceuticals and Medical Devices Agency (PMDA)
  • U.S. Department of Health and Human Services
  • US FDA